Keating M J, Smith T L, McCredie K B, Bodey G P, Hersh E M, Gutterman J U, Gehan E, Freireich E J
Cancer. 1981 Jun 15;47(12):2779-88. doi: 10.1002/1097-0142(19810615)47:12<2779::aid-cncr2820471204>3.0.co;2-0.
Combination chemotherapy with an anthracycline, Adriamycin or rubidazone, cytosine arabinoside, vincristine and prednisone resulted in a complete remission rate of 62% in 325 consecutive unselected adults with acute leukemia. The results by morphologic categories were 58% for acute myelogenous leukemia (AML), 70% for acute undifferentiated leukemia (AUL), and 77% for acute lymphoblastic leukemia (ALL). The median survival was 43 weeks. Ten percent of all patients are projected to be alive and in remission at five years. The median remission duration for the whole group was 51 weeks, durations being significantly longer for AML (60 wks) than ALL (30 wks) and AUL (21 wks). Central nervous system involvement was uncommon in AML (4%), but much more common in patients with AUL (37%) and ALL (32%). One in five complete responders with AML is projected to be in their first remission at five years off all chemotherapy. Age, sex, morphology, cytogenetic pattern, temperature of presentation, and presence of a documented preceding hematologic abnormality are found to be significant variables for response and survival.
采用阿霉素或柔红霉素、阿糖胞苷、长春新碱及强的松联合化疗，对325例未经选择的连续性成年急性白血病患者进行治疗，完全缓解率达62%。按形态学分类，急性髓细胞白血病（AML）的缓解率为58%，急性未分化白血病（AUL）为70%，急性淋巴细胞白血病（ALL）为77%。中位生存期为43周。预计所有患者中有10%在5年后仍存活且处于缓解状态。全组的中位缓解期为51周，AML（60周）的缓解期明显长于ALL（30周）和AUL（21周）。中枢神经系统受累在AML中不常见（4%），但在AUL患者（37%）和ALL患者（32%）中更为常见。预计每5例AML完全缓解患者中有1例在停止所有化疗5年后仍处于首次缓解状态。年龄、性别、形态学、细胞遗传学模式、就诊时体温以及是否有记录在案的既往血液学异常被发现是影响缓解和生存的重要变量。
